Tailoring antifungal doses for seniors: a precision approach
NCT ID NCT07496008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find the best dose of isavuconazole, an antifungal drug, for patients over 60 with invasive fungal infections. Researchers will monitor drug levels in the blood and adjust doses to improve treatment and reduce side effects. The goal is to create personalized dosing guidelines for this older population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isavuconazole
- What this could lead to
- If successful, this could lead to safer, more effective dosing guidelines for isavuconazole in older adults with invasive fungal infections.
- What could go wrong
- This is an early-stage observational study, not a large treatment trial. Results may not change current practice, and individual responses can vary widely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASION PULMONARY MYCOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
- Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
- Cresemba under the microscope: Real-World safety check for fungal infections
- COVID-19's hidden toll: fungal infections rise in transplant patients
- Real-World study examines Isavuconazole's effectiveness against deadly fungal infections
- Blood test could sniff out fatal fungus before It's too late